Blood Pressure Outcomes With Liraglutide Therapy

NCT01755572 on ClinicalTrials.gov · last registry update 2015-03-25

A small phase 4 — 22 participants, against a typical 75. The sponsor logged completion for January 2014. Primary outcome, as filed: Change in plasma ANP level at 1 Day. liraglutide is approved in the US, but not for hypertension — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Mount Sinai Hospital, Canada
Sponsor type: Other
Enrollment: 22
Started: 2013-01
Primary completion: 2014-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in plasma ANP level at 1 Day

Conditions studied

Type 2 Diabetes · Systolic Hypertension

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.